I'm a stock analyst with an MBA and a background in healthcare, bringing years of experience as a Registered Nurse dedicated to patient care. I've had the privilege of sharing my insights on Seeking Alpha since 2017. I am most interested in identifying underlying assumptions in stock valuations by emphasizing financial modeling techniques like DCF analysis. I then provide scenario-based forecasts to help readers gauge reasonable outcomes. I am influenced by books like Superforecasting and Antifragile. As su ...

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up for a free trial to Growth Stock Forum.Novo Nordisk ( NVO ) is out of investors' favor in the second half of th ...

Novo Nordisk (NVO) shares have lost 25.1% in the past three months compared with the industry's decline of 17.7%. The company has also underperformed the sector and the S&P 500 during the same time frame, as seen in the chart below. The stock is currently trading below both its 50 and 200-day moving averages. NVO Stock Underperforms the Industry, Sector & the S&P 500 Zacks Investment ResearchImage Source: Zacks Investment Research Novo Nordisk's stock price primarily dipped due to disappointing third-quarte ...

In today's article I will try to answer the question on whether the two premier diet drug companies stocks have finally stopped going down? I will look at two stocks (dietary drug is in parenthesis): Novo Nordisk NYSE:NVO (Wegovy) and Eli Lilly NYSE:LLY (Zepbound) Today I read this: WEIGHT-LOSS DRUG COVERAGE RISES AMONG LARGE US EMPLOYERS IN 2024: MERCER SURVEY 44% of US employers with 500+ employees now cover weight-loss drugs, up from 41% in 2023. Among employers with over 20,000 employees, 64% offer cove ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares. Over the last couple of years, Danish company Novo Nordisk (NVO 2.83%) has evolved from a relatively obscure pharmaceutical business to perhaps the biggest rising star in healthcare. The company's breakthroughs with glucagon-like peptide-1 (GLP-1) agonists gave birth to a host of blockbuster medications that are used to treat diabetes and obesity. Chief among its offerings are Ozempic ...

About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and onl ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium also includes the Zacks Style Scores. Wha ...

A few months ago, I published my investment thesis on Novo Nordisk ( NVO ), which I highly recommend reviewing before continuing with this article, as it provides my general outlook on the sector and I am an investor who relies on the fundamental aspects of companies. I enjoy being the owner of the world's best businesses with strong long-term projections. To achieve this, I conduct thorough research on the companies I invest in, placing significant importance on the sector, competitive advantages, and mana ...

Bagsværd, Denmark, 8 November 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S' 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 750.42 per share and has been calculated as the three-day volume weighted average market price from 6 November ...

Novo Nordisk A/S (NVO) reported third-quarter 2024 earnings of 90 cents per American Depositary Receipt (ADR), which marginally missed the Zacks Consensus Estimate of 91 cents. The company had reported earnings of 73 cents per ADR in the year-ago quarter.Revenues of $10.5 billion increased 21% in Danish kroner (DKK) and 23% at constant exchange rate (CER) in the reported quarter. However, total revenues also missed the Zacks Consensus Estimate of $10.7 billion. The year-over-year increase in revenues was dr ...